{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:10:36Z","timestamp":1791882636971,"version":"4.3.4"},"reference-count":32,"publisher":"American College of Physicians","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.acpjournals.org\/journal\/aim\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Intern Med"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.7326\/annals-25-01939","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T22:00:26Z","timestamp":1766440826000},"page":"168-176","source":"Crossref","is-referenced-by-count":23,"title":["Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1"],"prefix":"10.7326","volume":"179","author":[{"given":"Amy E.","family":"Colson","sequence":"first","affiliation":[{"name":"Community Resource Initiative, Boston, and Cambridge Health Alliance, Cambridge, Massachusetts (A.E.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon E.","family":"Crofoot","sequence":"additional","affiliation":[{"name":"The Crofoot Research Center, Houston, Texas (G.E.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ruane","sequence":"additional","affiliation":[{"name":"Ruane Clinical Research, Los Angeles, California (P.J.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti N.","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Immunology & Research Center, Fort Pierce, Florida (M.N.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2825-4988","authenticated-orcid":false,"given":"Alexandra W.","family":"Dretler","sequence":"additional","affiliation":[{"name":"Metro Infectious Disease Consultants, Decatur, Georgia (A.W.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-7491","authenticated-orcid":false,"given":"Ronald G.","family":"Nahass","sequence":"additional","affiliation":[{"name":"IDCare, Hillsborough, New Jersey (R.G.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary I.","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Prism Health North Texas, Dallas, Texas (G.I.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mezgebe","family":"Berhe","sequence":"additional","affiliation":[{"name":"North Texas Infectious Diseases Consultants, Dallas, Texas (M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsoon","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, George Washington University School of Medicine and Health Sciences, Washington, DC (A.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1980-2649","authenticated-orcid":false,"given":"Shauna","family":"Applin","sequence":"additional","affiliation":[{"name":"Community Health Care, Tacoma, Washington (S.A.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-2815","authenticated-orcid":false,"given":"Cynthia","family":"Brinson","sequence":"additional","affiliation":[{"name":"Central Texas Clinical Research, Austin, Texas (C.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-2002","authenticated-orcid":false,"given":"Dushyantha","family":"Jayaweera","sequence":"additional","affiliation":[{"name":"University of Miami, Miller School of Medicine, Miami, Florida (D.J.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-9493","authenticated-orcid":false,"given":"Kimberly A.","family":"Workowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, Georgia (K.A.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Shihadeh","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5247-3044","authenticated-orcid":false,"given":"Stephanie","family":"Klopfer","sequence":"additional","affiliation":[{"name":"Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Llamoso","sequence":"additional","affiliation":[{"name":"Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-5488","authenticated-orcid":false,"given":"Sharline","family":"Madera","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Dvory-Sobol","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Rhee","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Rhee","sequence":"additional","affiliation":[{"name":"Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-0644","authenticated-orcid":false,"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.J.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4285","reference":[{"key":"r1-ANNALS2501939","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.\n                      Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed at https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf on 21 February 2025."},{"key":"r2-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04103-2"},{"key":"r3-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu046"},{"key":"r4-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2014.945601"},{"key":"r5-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-024-00657-w"},{"key":"r6-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-023-00572-6"},{"key":"r7-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00051-6"},{"key":"r8-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy247"},{"key":"r9-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04423-x"},{"key":"r10-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03817-z"},{"key":"r11-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26099"},{"key":"r12-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13048"},{"key":"r13-ANNALS2501939","doi-asserted-by":"crossref","unstructured":"Shaik N, Zhang H, Girish S, et al\n                      . Simulations for once-weekly dosing of oral lenacapavir. Presented at AIDS 2022, Montreal, Quebec, Canada, 29 July\u20132 August 2022. Poster no. PESUB23","DOI":"10.1016\/j.jve.2022.100241"},{"key":"r14-ANNALS2501939","unstructured":"Zhang H, Mortensen E, Rhee M, et al\n                      . Evaluation of potential drug-drug interactions between islatravir and lenacapavir [Poster]. Presented at Conference on Retroviruses and Opportunistic Infections 2022, San Francisco, California, 12\u201316 February 2022. Poster no. 433."},{"key":"r15-ANNALS2501939","unstructured":"Squires KE, Correll TA, Robertson MN, et al\n                      . Effect of islatravir on total lymphocyte and lymphocyte subset counts [Abstract]. Presented at Conference on Retroviruses and Opportunistic Infections 2023, Seattle, Washington, 19\u201322 February 2023. Abstract no. 192."},{"key":"r16-ANNALS2501939","unstructured":"Vargo R, Robey S, Zang X, et al\n                      . Modeling to optimize islatravir QW dose in HIV virologically suppressed PWH [Abstract]. Presented at Conference on Retroviruses and Opportunistic Infections 2023, Seattle, Washington, 19\u201322 February 2023. Abstract no. 497."},{"key":"r17-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30822-0"},{"key":"r18-ANNALS2501939","unstructured":"Gilead Sciences\n                      . Sunlenca (lenacapavir) U.S. prescribing information. Accessed at www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/sunlenca\/sunlenca_pi.pdf on 15 August 2025."},{"key":"r19-ANNALS2501939","unstructured":"Gilead Sciences\n                      . Sunlenca (lenacapavir) EU summary of product characteristics. Accessed at www.ema.europa.eu\/en\/documents\/product-information\/sunlenca-epar-product-information_en.pdf on 15 August 2024."},{"key":"r20-ANNALS2501939","unstructured":"Gilead Sciences\n                      . Yeztugo (lenacapavir) U.S. prescribing information. Accessed at www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/yeztugo\/yeztugo_pi.pdf on 15 August 2025."},{"key":"r21-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"r22-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00291-0"},{"key":"r23-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"r24-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"r25-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00334-24"},{"key":"r26-ANNALS2501939","unstructured":"U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research\n                      . Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for industry. Accessed at www.fda.gov\/media\/86284\/download on 21 February 2025."},{"key":"r27-ANNALS2501939","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341x.1999.01202.x"},{"key":"r28-ANNALS2501939","unstructured":"Longo D, Pham M, Imperial M, et al\n                      . Modeling accurately predicts efficacious islatravir QW dose with no lymphocyte and CD4 changes [Abstract]. Presented at Conference on Retroviruses and Opportunistic Infections 2025, San Francisco, California, 9\u201312 March 2025. Abstract no. 643."},{"key":"r29-ANNALS2501939","unstructured":"Fox M, Mngqibisa R, Velez JD, et al\n                      . Switch to DOR\/ISL (100\/0.25 mg) QD from oral ART: an open-label phase III study in adults with HIV-1 [Abstract]. Presented at Conference on Retroviruses and Opportunistic Infections 2025, San Francisco, California, 9\u201312 March 2025. Abstract no. 204B."},{"key":"r30-ANNALS2501939","unstructured":"Fox M, Mills AM, Ramgopal M, et al\n                      . Switch to DOR\/ISL (100\/0.25 mg) QD from BIC\/FTC\/TAF: a blinded phase III study in adults with HIV-1 [Abstract]. Presented at Conference on Retroviruses and Opportunistic Infections 2025, San Francisco, California, 9\u201312 March 2025. Abstract no. 204A."},{"key":"r31-ANNALS2501939","doi-asserted-by":"crossref","unstructured":"Study to Compare an Oral Weekly Islatravir\/Lenacapavir Regimen With Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1) [clinical trial]. Accessed at https:\/\/clinicaltrials.gov\/study\/NCT06630286?term=NCT06630286&rank=1 on 11 November 2024.","DOI":"10.1007\/s40278-024-66078-x"},{"key":"r32-ANNALS2501939","unstructured":"Study to Compare an Oral Weekly Islatravir\/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (ISLEND-2) [clinical trial]. Accessed at https:\/\/clinicaltrials.gov\/study\/NCT06630299?term=NCT06630299&rank=1 on 11 November 2024."}],"container-title":["Annals of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.acpjournals.org\/doi\/pdf\/10.7326\/ANNALS-25-01939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.acpjournals.org\/doi\/full-xml\/10.7326\/ANNALS-25-01939","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T22:02:15Z","timestamp":1771279335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.acpjournals.org\/doi\/10.7326\/ANNALS-25-01939"}},"subtitle":["A Phase 2 Randomized Study"],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.7326\/ANNALS-25-01939"],"URL":"https:\/\/doi.org\/10.7326\/annals-25-01939","relation":{},"ISSN":["0003-4819","1539-3704"],"issn-type":[{"value":"0003-4819","type":"print"},{"value":"1539-3704","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}